show Abstracthide AbstractFor the treatment of AML, the main regime relies on intensive induction chemotherapy. About 60 - 85% cases under age 60 years respond completely to the initial induction, whereas, in the patients above 60 years, the response rate is 40 - 60%. Despite this response rate, resistance to the induction therapy and relapse of AML are frequently observed, and have been reported in up to 50% patients of <60 years age, and 80% patients of >80 years age. In this study, the investigation of multiple genetic markers (point mutations analysis, clonal evolution, mutational signatures etc.) will be carried out through the next generation DNA sequencing at initial diagnosis to decipher a link between genetic aberrations observed at initial diagnosis and relapse.